Lipopolysaccharides (LPSs) from bacterial infections can enhance the inflammatory response by stimulating both IL-6 and IL-1β pathways, exacerbating cardiovascular inflammation and disease progression through increased cytokine production and systemic inflammation. This evidence concerns the gene IL1B and bacterial infectious disease.